Dr Maria Mason, MD in Waldron, AR - General Practice

Dr Maria Mason, MD is a General Practice physician based in Waldron, Arkansas. Dr Maria Mason is licensed to practice in Arkansas (license number E0117) and her current practice location is 1341 W 6th St, Waldron, Arkansas. She can be reached at her office (for appointments etc.) via phone at (479) 314-1131.

NPI number for Dr Maria Mason is 1710903174 and her current mailing address is Po Box 17000, Fort Smith, Arkansas. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1710903174.

Contact Information

	Dr Maria Mason, MD
	1341 W 6th St, Waldron, AR 72958-7642
	(479) 314-1131
	(479) 314-1194

Physician's Profile

Full Name	Dr Maria Mason
Gender	Female
Speciality	General Practice
Location	1341 W 6th St, Waldron, Arkansas
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1710903174
Provider Enumeration Date: 07/15/2006
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Dr Maria Mason such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1710903174	NPI	-	NPPES
5J505	Other	AR	AR BCBS

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	E0117 (Arkansas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Maria Mason is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Maria Mason, MD Po Box 17000, Fort Smith, AR 72917-7000 Ph: (479) 314-1131	Dr Maria Mason, MD 1341 W 6th St, Waldron, AR 72958-7642 Ph: (479) 314-1131

News Archive

Chinese SFDA approves Abbott's XIENCE V drug eluting stent for treating coronary artery disease

Abbott (NYSE: ABT) announced today that the Chinese State Food and Drug Administration (SFDA) has approved its XIENCE V(R) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) - the leading cause of death in China. XIENCE V is the only drug eluting stent to have demonstrated superiority over the TAXUS(R) Paclitaxel-Eluting Coronary Stent System (TAXUS) in the primary endpoints of two randomized, pivotal (phase III) clinical trials.

WHO confirms pilot deployment of first-generation malaria vaccine in sub-Saharan Africa

The world's first malaria vaccine will be rolled out in pilot projects in sub-Saharan Africa, WHO confirmed today. Funding is now secured for the initial phase of the programme and vaccinations are due to begin in 2018.

Inadequate sleep linked to high blood pressure: Study

In the study, men with the lowest level of the deeper stages of slumber, known as slow-wave sleep, had an 80 percent higher chance of developing high blood pressure than men with the highest level of this restorative sleep. The link held regardless of other factors, such as obesity or how long the men slept.

African leaders renew commitment to providing HIV treatment, prevention services

"African leaders meeting on the sidelines of the 67th session of the United Nations General Assembly called Wednesday for innovative solutions to accelerate the response to AIDS, tuberculosis and malaria and to advance health for people on the continent," the U.N. News Centre reports.

Rev/Dex combo looks like a breakthrough treatment for multiple myeloma

Mayo Clinic Cancer Center investigators report that combination therapy with lenalidomide (Revlimid) and dexamethasone (combination is called Rev/Dex) looks like a breakthrough treatment for multiple myeloma. Results of a Phase II clinical trial were published online Aug. 23 in Blood.

Dr Maria Mason, MD - General Practice in Waldron, AR